{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:08:34Z","timestamp":1771315714511,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of IgG\u2010mediated diseases in the peri\u2010allogeneic transplant period remains challenging. Specifically, the presence of donor\u2010specific antibodies (DSA) is a major cause of graft failure and poor graft function; despite improvements in desensitization, it remains an unmet need. Similarly, there is no standard approach for the prevention of delayed RBC transfusion independence and pure red blood cell aplasia caused by IgG isoagglutinins after major ABO\u2010mismatched transplant. We describe the first use of the FcRn antagonist efgartigimod to assist in preventing both issues in a patient with high DSA undergoing major ABO\u2010mismatched transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A woman with molecular relapse of FLT3\u2010ITD+ AML with no available haploidentical donors and a poor donor search underwent a myeloablative stem cell transplant from a major ABO\u2010mismatched (A donor into O recipient), 6\/8 HLA\u2010matched unrelated donor. Prior to conditioning chemotherapy, DSA remained above a median fluorescent intensity (MFI) of 8000 despite rituximab, daratumumab, IVIG, and plasma exchange. Efgartigimod was given on days \u22123, +4, and +11 of transplant, resulting in a prompt decrease of DSA and anti\u2010A isohemagglutinins and successful engraftment, including rapid RBC transfusion independence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Desensitization strategies for patients with high DSA or high isohemagglutinins remain imperfect and time consuming. The use of FcRn antagonists such as efgartigimod, which reduce recycling of IgG, including pathogenic IgG antibodies, complements the plasma and lymphocyte depleting activity of conditioning therapy and posttransplant cyclophosphamide and may be an effective adjunct in the management of IgG\u2010mediated processes in the posttransplant period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.18374","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:05:37Z","timestamp":1754460337000},"page":"1978-1981","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adding the\n                    <scp>FcRn<\/scp>\n                    antagonist efgartigimod for the prevention of\n                    <scp>IgG<\/scp>\n                    \u2010mediated complications in the peri\u2010transplant period"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8876","authenticated-orcid":false,"given":"Dennis L.","family":"Cooper","sequence":"first","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhannine Alyssa","family":"Verceles","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taba","family":"Kheradmand","sequence":"additional","affiliation":[{"name":"Department of Surgery Montefiore Medical Center  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9506-6971","authenticated-orcid":false,"given":"Monika","family":"Paroder","sequence":"additional","affiliation":[{"name":"Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"de Castro","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Browne","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Moavero","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Kornblum","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto A.","family":"Sica","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-8986","authenticated-orcid":false,"given":"Lauren C.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Z.","family":"Peeke","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridhi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01932-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.09.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20004"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2312718"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010545"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01950-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02163-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.15300"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386670"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02202-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.07.015"},{"issue":"17","key":"e_1_2_7_14_1","first-page":"1693","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan SC","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_7_15_1","unstructured":"SpellmanS XuS Allbee\u2010JohnsonM OloyedeT.Current Uses and Outcomes of Cellular Therapies in the US: CIBMTR Summary Slides 2024."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0062-8"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.18374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:23:19Z","timestamp":1771312999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.18374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/trf.18374"],"URL":"https:\/\/doi.org\/10.1111\/trf.18374","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}